ARISTOCRAT: A randomised controlled phase II trial of temozolomide with or without cannabinoids in patients with recurrent glioblastoma
For copies of the latest and previous versions of documents distributed for this trial, please contact the ARISTOCRAT Trial Office.
Overview of ARISTOCRAT trial
| Chief Investigator: |
Professor Susan Short |
|---|
| Sponsor: |
University of Birmingham |
|---|
| Funder: |
The Brain Tumour Charity |
|---|
| Disease Site: |
Glioblastoma |
|---|
| Trial Type: |
Clinical Trial of an Investigational Medicinal Product |
|---|
| Status: |
Recruiting |
|---|
| EudraCT Number: |
2021-005214-34 |
|---|
| IRAS Number: |
1004427 |
|---|
| Recruitment Start Date: |
03-Feb-2023 |
|---|
| Anticipated Recruitment End Date: |
31-Oct-2024 |
|---|
| ClinicalTrials.gov Number: |
NCT05629702 |
|---|
| ISRCTN Number: |
11460478 |
|---|
| CRCTU Trial Management Team: |
Early Drug Development Team |
|---|
| Trial Email Address: |
aristocrat@trials.bham.ac.uk
|
|---|